Physician profile
Stephen G Divers
NPI 1760469407
$55,301.32
in general payments reported to CMS, 2019-2025
90 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,036 · 2020: $2,698 · 2021: $3,270 · 2022: $3,974 · 2023: $8,517 · 2024: $22K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $10K · Honoraria: $6,392 · Travel and Lodging: $1,639 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,071.00 |
| Food and Beverage | $10,204.19 |
| Honoraria | $6,392.00 |
| Travel and Lodging | $1,639.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $14,965.16 | 2019-2025 | Enhertu, Datroway |
| Pharmacosmos Therapeutics INC. | $11,166.45 | 2023-2025 | Monoferric, Cosela |
| Astrazeneca Pharmaceuticals Lp | $6,463.64 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Scientific Affairs, LLC | $1,934.75 | 2023-2025 | Talvey, Tecvayli, Carvykti |
| Amgen INC. | $1,854.51 | 2019-2024 | |
| Janssen Biotech, INC. | $1,426.78 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $1,251.99 | 2019-2025 | |
| Beigene USA, INC. | $1,144.80 | 2020-2025 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $1,010.18 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Pfizer INC. | $900.89 | 2019-2025 | |
| Spectrum Pharmaceuticals INC. | $820.82 | 2023-2025 | Rolvedon |
| Eisai INC. | $708.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $678.70 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Emd Serono, INC. | $634.93 | 2021-2025 | Bavencio |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $599.56 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $468.84 | 2019-2025 | Venclexta, Lupron Depot, Epkinly |
| Incyte Corporation | $465.15 | 2019-2025 | Jakafi, Monjuvi |
| Lilly USA, LLC | $452.51 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $441.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $424.33 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $344.96 | 2019-2025 | |
| Astellas Pharma US INC | $330.71 | 2019-2025 | Padcev, Xospata, Xtandi |
| Exelixis INC. | $313.84 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $310.15 | 2019-2023 | Tecentriq, Gavreto, Alecensa |
| Asd Specialty Healthcare, LLC | $308.49 | 2022-2025 | |
| Seagen INC. | $303.45 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Gilead Sciences, INC. | $248.40 | 2019-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $222.39 | 2020-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $216.68 | 2019-2024 | Ninlaro, Advate |
| Rigel Pharmaceuticals, INC. | $195.17 | 2021-2024 | Rezlidhia, Tavalisse |
| Sumitomo Pharma America, INC. | $194.05 | 2023-2025 | Orgovyx |
| Array Biopharma INC | $192.79 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Morphosys, US INC. | $192.57 | 2021-2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.11 | 2019-2025 | Gilotrif |
| Puma Biotechnology, INC. | $186.37 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $185.51 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $182.11 | 2019-2023 | Imbruvica |
| Kite Pharma, INC. | $149.81 | 2020-2023 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $137.80 | 2022-2025 | Libtayo |
| Beone Medicines USA, INC. | $131.68 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $123.98 | 2022-2025 | |
| Myovant Sciences INC. | $112.04 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $103.97 | 2019-2025 | Onivyde |
| Adaptive Biotechnologies Corporation | $93.55 | 2022 | |
| Sobi, INC | $90.35 | 2022-2025 | |
| Epizyme, INC. | $90.13 | 2020-2022 | |
| Fennec Pharmaceuticals, INC. | $82.27 | 2025 | Fyarro |
| Blueprint Medicines Corporation | $62.39 | 2022-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $62.31 | 2020-2022 | |
| Genmab U.S., INC. | $57.98 | 2023-2025 | Epkinly |
| Iovance Biotherapeutics, INC. | $53.98 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $52.29 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $51.22 | 2024-2025 | Provenge |
| Springworks Therapeutics, INC. | $50.77 | 2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $46.72 | 2021-2024 | Qinlock |
| Clovis Oncology, INC. | $46.70 | 2019-2020 | |
| Mirati Therapeutics, INC. | $46.61 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $45.30 | 2023-2025 | Orserdu |
| Amag Pharmaceuticals, INC. | $38.83 | 2021 | |
| Tersera Therapeutics LLC | $38.08 | 2023-2024 | Xermelo, Zoladex |
| Tesaro, INC. | $37.03 | 2019 | |
| Legend Biotech USA INC. | $36.50 | 2024-2025 | Carvykti |
| Pharmaessentia USA Corporation | $36.38 | 2022-2024 | Besremi |
| Celltrion USA INC. | $33.72 | 2024-2025 | Vegzelma |
| Aveo Pharmaceuticals, INC. | $33.41 | 2023-2024 | Fotivda |
| Dova Pharmaceuticals | $31.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $30.34 | 2022-2025 | |
| Tempus Ai, INC | $29.78 | 2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $27.10 | 2019 | |
| G1 Therapeutics, INC. | $26.60 | 2022-2023 | Cosela |
| Shield Therapeutics INC | $26.03 | 2023-2024 | Accrufer |
| Ucb, INC. | $25.73 | 2025 | Rystiggo |
| Helsinn Therapeutics (U.S.), INC. | $22.50 | 2019 | |
| Geron Corporation | $21.72 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $20.46 | 2023 | Empaveli |
| Sirtex Medical INC | $18.92 | 2024 | Sir-Spheres Microspheres |
| Taiho Oncology, INC. | $18.69 | 2025 | |
| Heron Therapeutics, INC. | $16.52 | 2021 | |
| Caris Mpi, INC. | $15.81 | 2025 | Mi Cancer Seek |
| Teva Pharmaceuticals USA, INC. | $15.21 | 2019 | |
| Acrotech Biopharma INC. | $14.91 | 2023 | Beleodaq |
| Kyowa Kirin, INC. | $13.49 | 2022 | |
| Foundation Medicine, INC. | $12.74 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.74 | 2023 | Odomzo, Yonsa |
| Blue Earth Diagnostics | $11.85 | 2021 | |
| Veracyte, INC. | $11.32 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$16,150.05 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Divers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.